177 related articles for article (PubMed ID: 9438228)
21. Treatment of depression--newer pharmacotherapies.
Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
[TBL] [Abstract][Full Text] [Related]
22. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
23. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
24. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
Hajós M; Fleishaker JC; Filipiak-Reisner JK; Brown MT; Wong EH
CNS Drug Rev; 2004; 10(1):23-44. PubMed ID: 14978512
[TBL] [Abstract][Full Text] [Related]
25. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of reboxetine in major depression.
Schatzberg AF
J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
[TBL] [Abstract][Full Text] [Related]
27. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
[TBL] [Abstract][Full Text] [Related]
28. Introduction. Reboxetine: a new selective antidepressant for the treatment of depression.
Montgomery SA; Schatzberg AF
J Clin Psychiatry; 1998; 59 Suppl 14():3. PubMed ID: 9818622
[No Abstract] [Full Text] [Related]
29. The need for new and better antidepressants: reboxetine a new option.
Dencker SJ
Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
[TBL] [Abstract][Full Text] [Related]
30. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
[TBL] [Abstract][Full Text] [Related]
31. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Nelson JC; Portera L; Leon AC
J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
33. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
Scates AC; Doraiswamy PM
Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
[TBL] [Abstract][Full Text] [Related]
34. The antidepressant efficacy of reboxetine in patients with severe depression.
Montgomery S; Ferguson JM; Schwartz GE
J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
[TBL] [Abstract][Full Text] [Related]
35. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
[TBL] [Abstract][Full Text] [Related]
36. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
Keller M
Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
[TBL] [Abstract][Full Text] [Related]
37. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
Berzewski H; Van Moffaert M; Gagiano CA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
[TBL] [Abstract][Full Text] [Related]
39. [Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline].
MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526675
[No Abstract] [Full Text] [Related]
40. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
Massana J; Möller HJ; Burrows GD; Montenegro RM
Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
